Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The findings, supported by clinical data, suggest that nadunolimab can enhance the efficacy of cancer vaccines and improve immunotherapy outcomes by reducing immunosuppressive cells and boosting anti-tumor immunity. This development could significantly impact cancer treatment, offering new avenues for overcoming resistance to immune therapies and improving patient prognoses.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program involves the antibody nadunolimab (CAN04), studied in combination with chemotherapy, targeting pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is developing CAN10 for autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
See more insights into CANTA stock on TipRanks’ Stock Analysis page.